PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

PeproMene-Bio-Study

More Like This

PR Newswire associated0

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA